OCUL · Ocular Therapeutix, Inc.
$10.49
-1.22% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-7.3
Dividend yield
—
Beta
0.97
Avg volume
3M
Employees
0K
Daily Change %
-1.22%
5 Days Change
7.80%
10 Days Change
9.34%
30 Days Change
17.52%
60 Days Change
12.45%
Month to Day Change
8.51%
Year to Day Change
-5.52%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — OCUL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-04
Latest call per bank · past 12 months
RBC Capital
Outperform$30.00
+182.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-04 | Chardan Capital | Maintains | Buy | $23.00 |
| 2026-06-25 | Chardan Capital | Maintains | Buy | $21.00 → $23.00 |
| 2026-06-18 | HC Wainwright & Co. | Reiterates | Buy | $21.00 → $25.00 |
| 2026-06-18 | Baird | Maintains | Outperform | $24.00 → $30.00 |
| 2026-05-06 | RBC Capital | Reiterates | Outperform | $30.00 |
| 2026-05-05 | Needham | Reiterates | Buy | $18.00 |
| 2026-04-13 | HC Wainwright & Co. | Reiterates | Buy | $21.00 |
| 2026-03-03 | Clear Street | Maintains | Buy | $21.00 → $28.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 51 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.4% above the 50-day MA ($9.86).
- Price vs 200-day MA: Trading 5.6% above the 200-day MA ($9.93).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.06) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($6.88) and high ($16.11).
OCUL Price Chart
Loading chart for OCUL…
Fundamentals
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.